Toward precision medicine in primary biliary cholangitis

Marco Carbone, Vincenzo Ronca, Savino Bruno, Pietro Invernizzi, George F. Mells

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Primary biliary cholangitis is a chronic, cholestatic liver disease characterized by a heterogeneous presentation, symptomatology, disease progression and response to therapy. In contrast, clinical management and treatment of PBC is homogeneous with a ‘one size fits all’ approach. The evolving research landscape, with the emergence of the -omics field and the availability of large patient cohorts are creating a unique opportunity of translational epidemiology. Furthermore, several novel disease and symptom-modifying agents for PBC are currently in development. The time is therefore ripe for precision medicine in PBC. In this manuscript we describe the concept of precision medicine; review current approaches to risk-stratification in PBC, and speculate how precision medicine in PBC might develop in the near future.

Original languageEnglish (US)
Pages (from-to)843-850
Number of pages8
JournalDigestive and Liver Disease
Volume48
Issue number8
DOIs
StatePublished - Aug 1 2016
Externally publishedYes

Fingerprint

Precision Medicine
Cholangitis
Disease Progression
Liver Diseases
Epidemiology
Therapeutics
Research

Keywords

  • Precision medicine
  • Primary biliary cholangitis
  • Risk-stratification

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Carbone, M., Ronca, V., Bruno, S., Invernizzi, P., & Mells, G. F. (2016). Toward precision medicine in primary biliary cholangitis. Digestive and Liver Disease, 48(8), 843-850. https://doi.org/10.1016/j.dld.2016.05.023

Toward precision medicine in primary biliary cholangitis. / Carbone, Marco; Ronca, Vincenzo; Bruno, Savino; Invernizzi, Pietro; Mells, George F.

In: Digestive and Liver Disease, Vol. 48, No. 8, 01.08.2016, p. 843-850.

Research output: Contribution to journalReview article

Carbone, M, Ronca, V, Bruno, S, Invernizzi, P & Mells, GF 2016, 'Toward precision medicine in primary biliary cholangitis', Digestive and Liver Disease, vol. 48, no. 8, pp. 843-850. https://doi.org/10.1016/j.dld.2016.05.023
Carbone M, Ronca V, Bruno S, Invernizzi P, Mells GF. Toward precision medicine in primary biliary cholangitis. Digestive and Liver Disease. 2016 Aug 1;48(8):843-850. https://doi.org/10.1016/j.dld.2016.05.023
Carbone, Marco ; Ronca, Vincenzo ; Bruno, Savino ; Invernizzi, Pietro ; Mells, George F. / Toward precision medicine in primary biliary cholangitis. In: Digestive and Liver Disease. 2016 ; Vol. 48, No. 8. pp. 843-850.
@article{76a657c106d2432d9a3a8c17a41afa42,
title = "Toward precision medicine in primary biliary cholangitis",
abstract = "Primary biliary cholangitis is a chronic, cholestatic liver disease characterized by a heterogeneous presentation, symptomatology, disease progression and response to therapy. In contrast, clinical management and treatment of PBC is homogeneous with a ‘one size fits all’ approach. The evolving research landscape, with the emergence of the -omics field and the availability of large patient cohorts are creating a unique opportunity of translational epidemiology. Furthermore, several novel disease and symptom-modifying agents for PBC are currently in development. The time is therefore ripe for precision medicine in PBC. In this manuscript we describe the concept of precision medicine; review current approaches to risk-stratification in PBC, and speculate how precision medicine in PBC might develop in the near future.",
keywords = "Precision medicine, Primary biliary cholangitis, Risk-stratification",
author = "Marco Carbone and Vincenzo Ronca and Savino Bruno and Pietro Invernizzi and Mells, {George F.}",
year = "2016",
month = "8",
day = "1",
doi = "10.1016/j.dld.2016.05.023",
language = "English (US)",
volume = "48",
pages = "843--850",
journal = "Digestive and Liver Disease",
issn = "1590-8658",
publisher = "Elsevier",
number = "8",

}

TY - JOUR

T1 - Toward precision medicine in primary biliary cholangitis

AU - Carbone, Marco

AU - Ronca, Vincenzo

AU - Bruno, Savino

AU - Invernizzi, Pietro

AU - Mells, George F.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Primary biliary cholangitis is a chronic, cholestatic liver disease characterized by a heterogeneous presentation, symptomatology, disease progression and response to therapy. In contrast, clinical management and treatment of PBC is homogeneous with a ‘one size fits all’ approach. The evolving research landscape, with the emergence of the -omics field and the availability of large patient cohorts are creating a unique opportunity of translational epidemiology. Furthermore, several novel disease and symptom-modifying agents for PBC are currently in development. The time is therefore ripe for precision medicine in PBC. In this manuscript we describe the concept of precision medicine; review current approaches to risk-stratification in PBC, and speculate how precision medicine in PBC might develop in the near future.

AB - Primary biliary cholangitis is a chronic, cholestatic liver disease characterized by a heterogeneous presentation, symptomatology, disease progression and response to therapy. In contrast, clinical management and treatment of PBC is homogeneous with a ‘one size fits all’ approach. The evolving research landscape, with the emergence of the -omics field and the availability of large patient cohorts are creating a unique opportunity of translational epidemiology. Furthermore, several novel disease and symptom-modifying agents for PBC are currently in development. The time is therefore ripe for precision medicine in PBC. In this manuscript we describe the concept of precision medicine; review current approaches to risk-stratification in PBC, and speculate how precision medicine in PBC might develop in the near future.

KW - Precision medicine

KW - Primary biliary cholangitis

KW - Risk-stratification

UR - http://www.scopus.com/inward/record.url?scp=84990982220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990982220&partnerID=8YFLogxK

U2 - 10.1016/j.dld.2016.05.023

DO - 10.1016/j.dld.2016.05.023

M3 - Review article

C2 - 27324985

AN - SCOPUS:84990982220

VL - 48

SP - 843

EP - 850

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

SN - 1590-8658

IS - 8

ER -